Trospium
As of the edition of 20 October 2026, Trospium is a small molecule: marketed, first approved in 1999 (FR); acts on CHRM2 and CHRM3; no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Small molecule
- Brand name
- Sanctura
- First approved
- 28 June 1999 (FR)
- Approvals on record
- 6 in 2 regions
- Holder of the most recent approval
- Bristol Myers Squibb; 3 holders in all
- Registered trials
- 59, 2 stopped early
- Disease areas
- Mental health; Nervous system; Pregnancy and women's health; Urinary and reproductive; Lungs and airways; Nutrition and metabolism
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Bristol Myers Squibb holds a later exclusivity on its own new formulation or combination product, ending 2029; it does not protect the original drug.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Trospium.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 3 | 5 | 0 |
| Phase 1 | 9 | 6 | 3 | 0 |
| Phase 2 | 4 | 2 | 2 | 0 |
| Phase 3 | 28 | 8 | 18 | 2 |
| Phase 4 | 10 | 7 | 3 | 0 |
| All trials | 59 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Acquired holder and Lead sponsor of trials | 2009 to now |